Jordi Remon: Adagrasib and pembrolizumab show impressive mPFS in KRAS G12C mutant NSCLC

Jordi Remon, Thoracic Oncologist at CIOCC Barcelona, shared a post on X:

“Adagrasib 400 mg and Pembrolizumab impressive mPFS in KRAS G12C mutant NSCLC and PDL1 >50% and good safety.

Better than IO or CT and IO alone. Good chem-free strategy for patients.

Await the ph3 trial.”